1.

論文

論文
Takamatsu, Hiroyuki ; Honda, Sumihisa ; Miyamoto, Toshihiro ; Yokoyama, Kenji ; Hagiwara, Shotaro ; Ito, Toshiro ; Tomita, Naoto ; Iida, Shinsuke ; Iwasaaki, Toshihiro ; Sakamaki, Hisashi ; Suzuki, Ritsuro ; Sunami, Kazutaka
出版情報: Cancer Science.  106  pp.179-185,  2015-02-01.  Japanese Cancer Association / Blackwell Publishing Ltd
URL: http://hdl.handle.net/2297/45512
概要: We evaluated the clinical significance of prognostic factors including the International Staging System (ISS) and modified European Group for Blood and Marrow Transplantation response criteria in 1650 Japanese patients with multiple myeloma (MM) who underwent upfront single autologous stem cell transplantation (ASCT). We categorized patients into two treatment cohorts: pre-novel agent era (1995-2006) and novel agent era (2008-2011). The combined percentage of pre-ASCT complete response and very good partial response cases (463 of 988, 47%) significantly increased during the novel agent era compared with the pre-novel agent era (164 of 527, 31%; P < 0.0001). The 2-year overall survival (OS) rate of 87% during the novel agent era was a significant improvement relative to that of 82% during the pre-novel agent era (P = 0.019). Although significant differences in OS were found among ISS stages during the pre-novel agent era, no significant difference was observed between ISS I and II (P = 0.107) during the novel agent era. The factors independently associated with a superior OS were female gender (P = 0.002), a good performance status (P = 0.024), lower ISS (P < 0.001), pre-ASCT response at least partial response (P < 0.001) and ASCT during the novel agent era (P = 0.017). These results indicate that the response rate and OS were significantly improved, and the ISS could not clearly stratify the prognoses of Japanese patients with MM who underwent upfront single ASCT during the novel agent era. © 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association. 続きを見る
2.

その他

その他
高松, 博幸 ; Takamatsu, Hiroyuki ; タカマツ, ヒロユキ
出版情報: 博士学位論文要旨 論文内容の要旨および論文審査結果の要旨/金沢大学大学院医学研究科.  平成19年7月  pp.41-041,  2007-07-01.  金沢大学
URL: http://hdl.handle.net/2297/19186
概要: 取得学位 : 博士(医学), 学位授与番号 : 医博甲第1831号, 学位授与年月日 : 平成19年3月22日, 学位授与大学 : 金沢大学, 主査教授 : 小泉 晶一, 副査教授 : 金子 周一, 山岸 正和
3.

論文

論文
Noda, Akihiro ; Takamatsu, Hiroyuki ; Murakami, Yoshihiro ; Yajima, Kazuyoshi ; Tatsumi, Mitsuyoshi ; Ichise, Rikiya ; Nishimura, Shintaro
出版情報: Journal of Nuclear Medicine.  44  pp.105-108,  2003-01-01.  THE SOCIETY OF NUCLEAR MEDICINE INC
URL: http://hdl.handle.net/2297/2782
概要: 金沢大学大学院医学系研究科<br />This study used PET to measure the time course of the brain concentration of 18F-labeled N-(4-a cetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960), a novel antidementia drug, after oral administration to conscious rhesus monkeys. Methods: Three young-adult male rhesus monkeys were tested. FK960 (0.1 mg/kg) containing about 370 MBq of 18F-FK960 was administered orally to each monkey. Dynamic PET images were acquired for 4 h from 5 min after the administration. Arterial blood samples were withdrawn during PET scanning and were analyzed by an automatic well γ-counter and thin-layer chromatography to determine the time course of authentic 18F-FK960 activity concentration in plasma. FK960 concentrations in brain and plasma were calculated in units of mol/L using the specific activity of FK960 preparations. Results: 18F-FK960 penetrated the blood-brain barrier and underwent perfusion-dependent distribution in the entire brain. Maximal concentrations in the brain and plasma were 1.11 ± 0.30 x 10-7 mol/L (at 3.0 ± 0.6 h after administration) and 4.04 ± 1.29 x 10-7 mol/L (at 2.0 ± 1.1 h after administration), respectively. Conclusion: We succeeded in measuring the FK960 concentration in the brains of conscious monkeys and in plasma after oral administration at a dose of 0.1 mg/kg. The results suggested that this method can measure the FK960 concentration in the human brain, and a potential use of the PET technique in drug development was demonstrated. 続きを見る
4.

論文

論文
Takamatsu, Hiroyuki ; Honda, Sumihisa ; Miyamoto, Toshihiro ; Yokoyama, Kenji ; Hagiwara, Shotaro ; Ito, Toshiro ; Tomita, Naoto ; Iida, Shinsuke ; Iwasaki, Toshihiro ; Sakamaki, Hisashi ; Suzuki, Ritsuro ; Sunami, Kazutaka
出版情報: Cancer science.  106  pp.179-185,  2015-02-01.  日本癌学会 = The Japanese Cancer Association / Blackwell Publishing Ltd
URL: http://hdl.handle.net/2297/43450
概要: We evaluated the clinical significance of prognostic factors including the International Staging System (ISS) and modified European Group for Blood and Marrow Transplantation response criteria in 1650 Japanese patients with multiple myeloma (MM) who underwent upfront single autologous stem cell transplantation (ASCT). We categorized patients into two treatment cohorts: pre-novel agent era (1995-2006) and novel agent era (2008-2011). The combined percentage of pre-ASCT complete response and very good partial response cases (463 of 988, 47%) significantly increased during the novel agent era compared with the pre-novel agent era (164 of 527, 31%; P < 0.0001). The 2-year overall survival (OS) rate of 87% during the novel agent era was a significant improvement relative to that of 82% during the pre-novel agent era (P = 0.019). Although significant differences in OS were found among ISS stages during the pre-novel agent era, no significant difference was observed between ISS I and II (P = 0.107) during the novel agent era. The factors independently associated with a superior OS were female gender (P = 0.002), a good performance status (P = 0.024), lower ISS (P < 0.001), pre-ASCT response at least partial response (P < 0.001) and ASCT during the novel agent era (P = 0.017). These results indicate that the response rate and OS were significantly improved, and the ISS could not clearly stratify the prognoses of Japanese patients with MM who underwent upfront single ASCT during the novel agent era. © 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association. 続きを見る
5.

論文

論文
Takamatsu, Hiroyuki ; Araki, Raita ; Nishimura, Ryosei ; Yachie, Akihiro ; Espinoza, J. Luis ; Okumura, Hirokazu ; Yoshida, Takashi ; Kuzushima, Kiyotaka ; Nakao, Shinji
出版情報: Journal of Clinical Virology.  80  pp.82-86,  2016-06-01.  Elsevier
URL: http://hdl.handle.net/2297/45519
概要: Leukemic Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative diseases (PTLD) following allogeneic hematopoietic stem cell transplantation are extremely rare. We can successfully treat an EBV-associated leukemic lymphoma patient with rituximab, cidofovir, and donor lymphocyte infusion (DLI). In the present case, EBV-specific T cells that were present in the peripheral blood before rituximab administration treatment rapidly increased after DLI in association with a decrease in the EBV-DNA load. © 2016 Elsevier B.V.<br />Embargo Period 12 months 続きを見る
6.

論文

論文
Takamatsu, Hiroyuki ; Yagasaki, Hiroshi ; Takahashi, Yoshiyuki ; Hama, Asahito ; Saikawa, Yutaka ; Yachie, Akihiro ; Koizumi, Shoichi ; Kojima, Seiji ; Nakao, Shinji
出版情報: European Journal of Haematology.  86  pp.541-545,  2011-06-01.  Wiley-Blackwell
URL: http://hdl.handle.net/2297/28340
概要: 金沢大学医薬保健研究域医学系<br />A 1-yr-old Japanese male infant developed hepatitis-associated aplastic anemia (AA), and anti- thymocyte globulin (ATG) plus cyclosporine A (CsA) was administered without any appreciable effects. Laboratory examination of the patient's serum obtained before therapy revealed various autoantibodies, such as PA-IgG, anti-platelets, anti-single-stranded DNA (ssDNA), and anti-double-stranded DNA (dsDNA) antibodies (Abs) in addition to anti-DRS-1 Abs and anti-moesin Abs, both of which are known to be detectable in approximately 40% of all patients presenting with AA. He was therefore treated with 17.5mg/kg/d rituximab 5.5months after ATG/CsA therapy. The same rituximab therapy was repeated three times once a month thereafter. His neutrophil counts started to increase 50d after the first rituximab therapy and he achieved a complete remission at 16months after the last rituximab administration. All of the autoantibodies including anti-ssDNA, dsDNA, DRS-1, and moesin became undetectable when he attained the remission. Anti-CD20 monoclonal antibody therapy may be effective in a subset of patients with AA characterized by the presence of autoantibodies. © 2011 John Wiley & Sons A/S. 続きを見る
7.

論文

論文
太田, 良子 ; 島田, 啓子 ; 青木, 剛 ; 大畑, 欣也 ; 高松, 博幸 ; 近藤, 恭夫 ; 山﨑, 宏人 ; Ota, Yoshiko ; Shimada, Keiko ; Aoki, Go ; Ohata, Kinya ; Takamatsu, Hiroyuki ; Kondo, Yukio ; Yamazaki, Hirohito
出版情報: Journal of wellness and health care = Journal of wellness and health care.  41  pp.129-137,  2018-01-31.  Wellness and Health Care Society — ウェルネス・ヘルスケア学会
URL: http://hdl.handle.net/2297/00050129
概要: 目的造血器腫瘍は治療前に妊孕性温存の手段がとれない場合があり、その人々への支援のため、女性造血器腫瘍サバイバーが、病の中で子どもを持つことへの思いをどのように抱いているか明らかにすることを目的とする。対象と方法18 歳から 35 歳の間に造 血器腫瘍と診断され、抗がん剤治療または分子標的薬治療を受けて、寛解中の女性 10 名に対して半構成的面接を行い、対話構築主義に基づいたライフストーリー法で分析した。結果女性造血器腫瘍サバイバーが、結婚を視野に入れていないときは、告知時に【命の危機の前に薄らぐ将来の子どもを持つことの重要性】を感じ、寛解すると【回復した月経に伴う妊孕性への安心感と消えない不妊への不安】が生じた。結婚を考えるにつれて【念のため医師に妊娠可能かを聞く心配】が拭いきれず、不妊は家族形成の契機としての結婚の意味を失うため、【結婚前に子どもを持てないことを知る苦悩】、【病の受け入れを揺るがす子どもを持てない現実への恨み】を抱くようになった。結婚後では【子どもを持てるかより、先立つ死に向かう不安】が強かった。その後、子どもを授かるも【病の治療による胎児の障害への懸念】は続いた。結論女性の人生で “ 子どもを持つことへの思い ” が、結婚を考える時期と病の回復段階の 2 軸を中心に思いが変容していた。そのため一時的な思いではなく、女性の人生全体を考えた理解の仕方というものの重要性が示唆された。<br />PurposeFertility often cannot be preserved in patients with hematopoietic tumors. This study was performed to clarify the thoughts of female hematopoietic tumor survivor on child bearing.MethodsThe study population consisted of 10 women diagnosed with hematopoietic tumors between 18 and 35 years of age, undergoing anticancer drug treatment or molecular targeted therapy, and currently in remission. We conducted a semi-structured interview with the Life Story method based on dialogue building.ResultsWhen not considering marriage, they reported that “The importance of having a child faded compared with the crisis of life” at diagnosis, and “Relief obtained by cure of amenorrhea occurred during remission and indelible anxiety regarding infertility.” When wishing to get married, “Fear concerning infertility, asking the doctor if they can become pregnant” cannot be forgotten. Infertility results in loss of the meaning of marriage as a trigger for family formation, so the respondents reported “Anguish to know that I cannot have children before marriage” and “Resentment toward the reality of infertility that affects acceptance of disease”. After marriage, “Anxiety heading toward death, rather than whether I will have children” was strong. During pregnancy “Concerns about fetal disorders due to treatment of the disease” continued.ConclusionIn the life of a woman, thoughts of having children were transformed around two axes, i.e., the time to consider marriage and the stage of recovery from the disease. Therefore, rather than just capturing temporary thoughts, how to understand the whole life of women was suggested to be important. 続きを見る
8.

論文

論文
高松, 博幸 ; Takamatsu, Hiroyuki
出版情報: 平成23(2011)年度 科学研究費補助金 基盤研究(C) 研究成果報告書 = 2011 Fiscal Year Final Research Report.  2009-2011  pp.4p.-,  2012-05-21.  金沢大学医薬保健研究域医学系
URL: http://hdl.handle.net/2297/00050946
概要: モエシンKOマウスは以下の表現型異常が認められた。末梢血白血球減少、貧血、体重減少と脾腫大、骨髄造血幹細胞の減少、骨髄・脾臓のB細胞・形質細胞の減少とT細胞の増加、脾臓の濾胞構造の不明瞭化である。一方、モエシンKOマウスにモエシン蛋白質を免 疫したところ、抗モエシン抗体が産生された。前処置後の野生型マウスに抗モエシン抗体を産生する脾臓・骨髄細胞を骨髄内移植したところ、野生型マウスに抗モエシン抗体産生、TNFαとIFNγ濃度の上昇、白血球減少がみとめられたが、血小板減少と貧血は認められなかった。<br />Moesin KO mice grew normally. However, the body weight of moesin KO mice was lower than that of WT mice. Complete blood counts of moesin KO mice revealed leukocytopenia and macrocytic anemia ; platelet counts were comparable. Moesin KO mouse spleens were heavier than those of WT mice and follicle formation in spleens of moesin KO mice were obscure with increased CD3^+lymphocytes and reduced CD19^+lymphocytes as compared with WT mice. BM of moesin KO mice was normocellular and characterized by increased CD3^+lymphocytes and reduced CD19^+lymphocytes as seen in spleens of moesin KO mice. The number of lineage negative, Sca-1^+, and c-Kit^+(LSK) mouse HSCs in moesin KO BM tended to be lower than that of WT mice. Moesin KO spleen/BM cells capable of producing anti-moesin antibodies were infused into BM of WT B6 male mice. Transplanted mice showed leukocytopenia and increase of TNFαand IFNγin plasma compared to WT B6 male mice transplanted with WT spleen/BM cells, but anemia and thrombocytopenia were not observed.<br />研究課題/領域番号:21591237, 研究期間(年度):2009-2011 続きを見る
9.

論文

論文
高松, 博幸 ; Takamatsu, Hiroyuki
出版情報: 平成29(2017)年度 科学研究費補助金 基盤研究(C) 研究成果報告書 = 2017 Fiscal Year Final Research Report.  2015-04-01 - 2018-03-31 
URL: http://hdl.handle.net/2297/00050945
概要: 金沢大学医薬保健研究域医学系<br />多発性骨髄腫症例での微小残存病変(MRD)検出する方法である次世代シークエンサー(NGS)法、マルチパラメーターフローサイトメトリー(MFC)法を確立し、骨髄や自家移植片中のMRD検査を実 施した。その結果、MRDが陰性の場合に極めて良好な無増悪生存や全生存となった。その結果に基づいて、NGSとMFCによるMRD検出の臨床的意義を検証する多施設前向き臨床研究(UMIN-CTR ID: UMIN000022238)を開始した。一方、NGSやMFCでMRDが陰性となった極めて深い奏効を達成した多発性骨髄腫症例の血清中で検出される抗X抗体のターゲット抗原Xは、癌精巣抗原の1種であることを明らかにした。<br />We demonstrated the clinical value of minimal residual disease (MRD) detection in multiple myeloma (MM) patients using next-generation sequencing (NGS) and multiparameter flow cytometry (MFC). When MRD negativity in bone marrow and/or autografts of MM patients was achieved, the progression-free survival and overall survival were dramatically improved. Based on the results, we have started the clinical study "Prognostic value of minimal residual disease detection using multiparameter flow cytometry (EuroFlow method) in patients with multiple myeloma who underwent autologous stem cell transplantation: comparison with sequencing-based method (UMIN-CTR ID: UMIN000022238)". On the other hand, we clarified that anti-X antibody which is detected in the sera of MRD negative MM patients binds to a cancer-testis antigen X.<br />研究課題/領域番号:15K08644, 研究期間(年度):2015-04-01 - 2018-03-31 続きを見る